AG-946
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 82 patients (estimated)
- Sponsors
- Agios Pharmaceuticals, Inc.
- Tags
- Pyruvate Kinase (PKR), Placebo, Randomization
- Trial Type
- Treatment
- Last Update
- 2 days ago
- SparkCures ID
- 1361
- NCT Identifier
- NCT05490446
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.